256 related articles for article (PubMed ID: 30734284)
1. Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016.
Orumaa M; Leinonen MK; Campbell S; Møller B; Myklebust TÅ; Nygård M
Int J Cancer; 2019 Nov; 145(10):2629-2638. PubMed ID: 30734284
[TBL] [Abstract][Full Text] [Related]
2. Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.
Cleveland AA; Gargano JW; Park IU; Griffin MR; Niccolai LM; Powell M; Bennett NM; Saadeh K; Pemmaraju M; Higgins K; Ehlers S; Scahill M; Johnson Jones ML; Querec T; Markowitz LE; Unger ER;
Int J Cancer; 2020 Feb; 146(3):810-818. PubMed ID: 30980692
[TBL] [Abstract][Full Text] [Related]
3. Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting.
Landy R; Schiffman M; Sasieni PD; Cheung LC; Katki HA; Rydzak G; Wentzensen N; Poitras NE; Lorey T; Kinney WK; Castle PE
Int J Cancer; 2020 Feb; 146(3):617-626. PubMed ID: 30861114
[TBL] [Abstract][Full Text] [Related]
4. Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Northern California.
Befano B; Wentzensen N; Lorey T; Poitras N; Cheung LC; Schiffman M; Clarke MA; Cohen C; Kinney W; Locke A; Castle PE
Gynecol Oncol; 2024 May; 184():89-95. PubMed ID: 38301311
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
6. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
8. Incidence of cervical precancerous lesions and cervical cancer in Denmark from 2000 to 2019: Population impact of multi-cohort vaccination against human papillomavirus infection.
Ring LL; Munk C; Galanakis M; Tota JE; Thomsen LT; Kjaer SK
Int J Cancer; 2023 Apr; 152(7):1320-1327. PubMed ID: 36250312
[TBL] [Abstract][Full Text] [Related]
9. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
Song F; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
BMC Cancer; 2022 Jan; 22(1):42. PubMed ID: 34991494
[TBL] [Abstract][Full Text] [Related]
10. Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008-2014.
McClung NM; Gargano JW; Bennett NM; Niccolai LM; Abdullah N; Griffin MR; Park IU; Cleveland AA; Querec TD; Unger ER; Markowitz LE;
Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):602-609. PubMed ID: 30792242
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus in invasive cervical cancer and cervical intraepithelial neoplasia 2 and 3 in Venezuela: a cross-sectional study.
Sánchez-Lander J; Cortiñas P; Loureiro CL; Pujol FH; Medina F; Capote-Negrín L; Bianchi G; García-Barriola V; Ruiz-Benni A; Avilán-Rovira J; Acosta H
Cancer Epidemiol; 2012 Oct; 36(5):e284-7. PubMed ID: 22608058
[TBL] [Abstract][Full Text] [Related]
12. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Detection of Cervical Cancer and Precancer Through Use of Imaged Liquid-Based Cytology in Routine Cytology and HPV Cotesting.
Austin RM; Onisko A; Zhao C
Am J Clin Pathol; 2018 Oct; 150(5):385-392. PubMed ID: 30137189
[TBL] [Abstract][Full Text] [Related]
14. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.
Sørbye SW; Fismen S; Gutteberg TJ; Mortensen ES; Skjeldestad FE
BMJ Open; 2016 Aug; 6(8):e011981. PubMed ID: 27515759
[TBL] [Abstract][Full Text] [Related]
15. High-Risk HPV Testing in Primary Screening for Cervical Cancer in the Public Health System, São Paulo, Brazil.
Levi JE; Martins TR; Longatto-Filho A; Cohen DD; Cury L; Fuza LM; Villa LL; Eluf-Neto J
Cancer Prev Res (Phila); 2019 Aug; 12(8):539-546. PubMed ID: 31189569
[TBL] [Abstract][Full Text] [Related]
16. A Pooled Analysis to Compare the Clinical Characteristics of Human Papillomavirus-positive and -Negative Cervical Precancers.
Castle PE; Pierz AJ; Adcock R; Aslam S; Basu PS; Belinson JL; Cuzick J; El-Zein M; Ferreccio C; Firnhaber C; Franco EL; Gravitt PE; Isidean SD; Lin J; Mahmud SM; Monsonego J; Muwonge R; Ratnam S; Safaeian M; Schiffman M; Smith JS; Swarts A; Wright TC; Van De Wyngard V; Xi LF
Cancer Prev Res (Phila); 2020 Oct; 13(10):829-840. PubMed ID: 32655005
[TBL] [Abstract][Full Text] [Related]
17. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
[TBL] [Abstract][Full Text] [Related]
18. The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.
Silver MI; Schiffman M; Fetterman B; Poitras NE; Gage JC; Wentzensen N; Lorey T; Kinney WK; Castle PE
Cancer; 2016 Dec; 122(23):3682-3686. PubMed ID: 27657992
[TBL] [Abstract][Full Text] [Related]
19. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
[TBL] [Abstract][Full Text] [Related]
20. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
Khan MJ; Castle PE; Lorincz AT; Wacholder S; Sherman M; Scott DR; Rush BB; Glass AG; Schiffman M
J Natl Cancer Inst; 2005 Jul; 97(14):1072-9. PubMed ID: 16030305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
